Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Michigan: - Saint Joseph Mercy Hospital — Ann Arbor, Michigan
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- McLaren Cancer Institute-Bay City — Bay City, Michigan
- McLaren Cancer Institute-Bloomfield — Bloomfield, Michigan
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Michigan: - University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
- Trinity Health Grand Rapids Hospital — Grand Rapids, Michigan
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
- Children's Hospital of Michigan — Detroit, Michigan
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
- Corewell Health Children's — Royal Oak, Michigan
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Michigan: - University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Michigan: - University of Michigan Hospital — Ann Arbor, Michigan
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Michigan: - Henry Ford Hospital — Detroit, Michigan
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Michigan: - Henry Ford Health System — Detroit, Michigan
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Michigan: - South Texas Accelerated Research Therapeutics (START) Midwest — Grand Rapids, Michigan
Phase 2 Recruiting Network
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual app…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06319027
Sites in Michigan: - University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
Phase 2 Recruiting Industry
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified …
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT04775485
Sites in Michigan: - CS Mott Children's Hospital — Ann Arbor, Michigan
Phase 2 Recruiting Academic/Other
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in Michigan: - C.S. Mott Children's Hospital — Ann Arbor, Michigan
Phase 2 Recruiting Academic/Other
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05843253
Sites in Michigan: - C.S. Mott Children's Hospital — Ann Arbor, Michigan
Phase 2 Recruiting Academic/Other
This study is being done to see if adding GLIADEL to the site where the tumor was removed works as well as just having the tumor removed with radiation treatment done within six weeks after the surgery to keep the cancer from coming back.
Sponsor: University of Nebraska
NCT ID: NCT04222062
Sites in Michigan: - Henry Ford — Detroit, Michigan
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
- Henry Ford Cancer Institute — Detroit, Michigan
- START - Midwest Cancer Research Center — Grand Rapids, Michigan
Phase 1 Recruiting Industry
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Sponsor: A2A Pharmaceuticals Inc.
NCT ID: NCT06136884
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 1 Recruiting Academic/Other
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary…
Sponsor: Sabine Mueller, MD, PhD
NCT ID: NCT04732065
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 1 Recruiting Academic/Other
This phase I trial investigates the side effects of chemotherapy and cellular immunotherapy in treating children with IL13Ralpha2 positive brain tumors that have come back after a period of improvement (recurrent) or do not respond to trea…
Sponsor: City of Hope Medical Center
NCT ID: NCT04510051
Sites in Michigan: - C.S. Mott Children's Hospital, University of Michigan — Ann Arbor, Michigan
Phase 1 Recruiting Academic/Other
This phase I trial tests the safety, side effects and best dose of AdV-HSV1-TK and AdV-Flt3L in combination with valacyclovir for the treatment of patients with primary cancerous (malignant) brain tumors that can be removed by surgery (res…
Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT06914479
Sites in Michigan: - University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
Recruiting Industry
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT04427384
Sites in Michigan: - Henry Ford Health System — Detroit, Michigan
Recruiting Academic/Other
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligi…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05839379
Sites in Michigan: - C.S. Mott Children's Hospital — Ann Arbor, Michigan